The global Inactivated Influenza Virus Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Inactivated Influenza Virus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Influenza Virus Vaccine.

Report Scope

The Inactivated Influenza Virus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Inactivated Influenza Virus Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Inactivated Influenza Virus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Inactivated Influenza Virus Vaccine Market Report

Report Metric	Details
Report Name	Inactivated Influenza Virus Vaccine Market
CAGR	5%
Segment by Type	Whole Virus Vaccine Subunit Vaccine
Segment by Application	Hospital Clinic
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd, Beijing Kexing Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd, Hualan Bio Vaccines Co., Ltd, Dalian Yalifeng Biopharmaceutical Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Emmi Chengxin Biopharmaceutical Co., Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Inactivated Influenza Virus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Inactivated Influenza Virus Vaccine Market report?

Ans: The main players in the Inactivated Influenza Virus Vaccine Market are CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd, Beijing Kexing Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd, Hualan Bio Vaccines Co., Ltd, Dalian Yalifeng Biopharmaceutical Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Emmi Chengxin Biopharmaceutical Co., Ltd

What are the Application segmentation covered in the Inactivated Influenza Virus Vaccine Market report?

Ans: The Applications covered in the Inactivated Influenza Virus Vaccine Market report are Hospital, Clinic

What are the Type segmentation covered in the Inactivated Influenza Virus Vaccine Market report?

Ans: The Types covered in the Inactivated Influenza Virus Vaccine Market report are Whole Virus Vaccine, Subunit Vaccine

1 Inactivated Influenza Virus Vaccine Market Overview

1.1 Product Overview and Scope of Inactivated Influenza Virus Vaccine

1.2 Inactivated Influenza Virus Vaccine Segment by Type

1.2.1 Global Inactivated Influenza Virus Vaccine Market Value Comparison by Type (2024-2030)

1.2.2 Whole Virus Vaccine

1.2.3 Subunit Vaccine

1.3 Inactivated Influenza Virus Vaccine Segment by Application

1.3.1 Global Inactivated Influenza Virus Vaccine Market Value by Application: (2024-2030)

1.3.2 Hospital

1.3.3 Clinic

1.4 Global Inactivated Influenza Virus Vaccine Market Size Estimates and Forecasts

1.4.1 Global Inactivated Influenza Virus Vaccine Revenue 2019-2030

1.4.2 Global Inactivated Influenza Virus Vaccine Sales 2019-2030

1.4.3 Global Inactivated Influenza Virus Vaccine Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Inactivated Influenza Virus Vaccine Market Competition by Manufacturers

2.1 Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2019-2024)

2.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Inactivated Influenza Virus Vaccine Average Price by Manufacturers (2019-2024)

2.4 Global Inactivated Influenza Virus Vaccine Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Product Type & Application

2.7 Inactivated Influenza Virus Vaccine Market Competitive Situation and Trends

2.7.1 Inactivated Influenza Virus Vaccine Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Inactivated Influenza Virus Vaccine Players Market Share by Revenue

2.7.3 Global Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Inactivated Influenza Virus Vaccine Retrospective Market Scenario by Region

3.1 Global Inactivated Influenza Virus Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Inactivated Influenza Virus Vaccine Global Inactivated Influenza Virus Vaccine Sales by Region: 2019-2030

3.2.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2019-2024

3.2.2 Global Inactivated Influenza Virus Vaccine Sales by Region: 2025-2030

3.3 Global Inactivated Influenza Virus Vaccine Global Inactivated Influenza Virus Vaccine Revenue by Region: 2019-2030

3.3.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2019-2024

3.3.2 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2025-2030

3.4 North America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country

3.4.1 North America Inactivated Influenza Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2019-2030)

3.4.3 North America Inactivated Influenza Virus Vaccine Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Inactivated Influenza Virus Vaccine Market Facts & Figures by Country

3.5.1 Europe Inactivated Influenza Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2019-2030)

3.5.3 Europe Inactivated Influenza Virus Vaccine Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Inactivated Influenza Virus Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Inactivated Influenza Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2019-2030)

3.6.3 Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country

3.7.1 Latin America Inactivated Influenza Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Inactivated Influenza Virus Vaccine Sales by Country (2019-2030)

3.7.3 Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Inactivated Influenza Virus Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2019-2030)

3.8.3 Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2019-2030)

4.1.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2019-2024)

4.1.2 Global Inactivated Influenza Virus Vaccine Sales by Type (2025-2030)

4.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2019-2030)

4.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2019-2030)

4.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Type (2019-2024)

4.2.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2025-2030)

4.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2019-2030)

4.3 Global Inactivated Influenza Virus Vaccine Price by Type (2019-2030)

5 Segment by Application

5.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2019-2030)

5.1.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2019-2024)

5.1.2 Global Inactivated Influenza Virus Vaccine Sales by Application (2025-2030)

5.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2019-2030)

5.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2019-2030)

5.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Application (2019-2024)

5.2.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2025-2030)

5.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2019-2030)

5.3 Global Inactivated Influenza Virus Vaccine Price by Application (2019-2030)

6 Key Companies Profiled

6.1 CSL

6.1.1 CSL Corporation Information

6.1.2 CSL Description and Business Overview

6.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio

6.1.5 CSL Recent Developments/Updates

6.2 GSK

6.2.1 GSK Corporation Information

6.2.2 GSK Description and Business Overview

6.2.3 GSK Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.2.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio

6.2.5 GSK Recent Developments/Updates

6.3 Sanofi Pasteur

6.3.1 Sanofi Pasteur Corporation Information

6.3.2 Sanofi Pasteur Description and Business Overview

6.3.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio

6.3.5 Sanofi Pasteur Recent Developments/Updates

6.4 Mylan

6.4.1 Mylan Corporation Information

6.4.2 Mylan Description and Business Overview

6.4.3 Mylan Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio

6.4.5 Mylan Recent Developments/Updates

6.5 AstraZeneca

6.5.1 AstraZeneca Corporation Information

6.5.2 AstraZeneca Description and Business Overview

6.5.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.5.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio

6.5.5 AstraZeneca Recent Developments/Updates

6.6 Pfizer

6.6.1 Pfizer Corporation Information

6.6.2 Pfizer Description and Business Overview

6.6.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio

6.6.5 Pfizer Recent Developments/Updates

6.7 Johnson & Johnson

6.6.1 Johnson & Johnson Corporation Information

6.6.2 Johnson & Johnson Description and Business Overview

6.6.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio

6.7.5 Johnson & Johnson Recent Developments/Updates

6.8 Jiangsu Jindik Biotechnology Co., Ltd

6.8.1 Jiangsu Jindik Biotechnology Co., Ltd Corporation Information

6.8.2 Jiangsu Jindik Biotechnology Co., Ltd Description and Business Overview

6.8.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.8.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments/Updates

6.9 Beijing Kexing Biological Products Co., Ltd

6.9.1 Beijing Kexing Biological Products Co., Ltd Corporation Information

6.9.2 Beijing Kexing Biological Products Co., Ltd Description and Business Overview

6.9.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.9.5 Beijing Kexing Biological Products Co., Ltd Recent Developments/Updates

6.10 Jiangsu Kangrun Biotechnology Co., Ltd

6.10.1 Jiangsu Kangrun Biotechnology Co., Ltd Corporation Information

6.10.2 Jiangsu Kangrun Biotechnology Co., Ltd Description and Business Overview

6.10.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.10.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments/Updates

6.11 Hualan Bio Vaccines Co., Ltd

6.11.1 Hualan Bio Vaccines Co., Ltd Corporation Information

6.11.2 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview

6.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments/Updates

6.12 Dalian Yalifeng Biopharmaceutical Co., Ltd

6.12.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Corporation Information

6.12.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview

6.12.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.12.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments/Updates

6.13 Shanghai Institute of Biological Products Co., Ltd

6.13.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information

6.13.2 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview

6.13.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.13.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates

6.14 Changchun Institute of Biological Products Co., Ltd

6.14.1 Changchun Institute of Biological Products Co., Ltd Corporation Information

6.14.2 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview

6.14.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.14.5 Changchun Institute of Biological Products Co., Ltd Recent Developments/Updates

6.15 Lanzhou Institute of Biological Products Co., Ltd

6.15.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information

6.15.2 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview

6.15.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.15.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates

6.16 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd

6.16.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Corporation Information

6.16.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview

6.16.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.16.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.16.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments/Updates

6.17 Emmi Chengxin Biopharmaceutical Co., Ltd

6.17.1 Emmi Chengxin Biopharmaceutical Co., Ltd Corporation Information

6.17.2 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview

6.17.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.17.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio

6.17.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Inactivated Influenza Virus Vaccine Industry Chain Analysis

7.2 Inactivated Influenza Virus Vaccine Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Inactivated Influenza Virus Vaccine Production Mode & Process

7.4 Inactivated Influenza Virus Vaccine Sales and Marketing

7.4.1 Inactivated Influenza Virus Vaccine Sales Channels

7.4.2 Inactivated Influenza Virus Vaccine Distributors

7.5 Inactivated Influenza Virus Vaccine Customers

8 Inactivated Influenza Virus Vaccine Market Dynamics

8.1 Inactivated Influenza Virus Vaccine Industry Trends

8.2 Inactivated Influenza Virus Vaccine Market Drivers

8.3 Inactivated Influenza Virus Vaccine Market Challenges

8.4 Inactivated Influenza Virus Vaccine Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Beijing Kexing Biological Products Co., Ltd

Shanghai Institute of Biological Products Co., Ltd.

Changchun Institute of Biological Products Co., Ltd.

Lanzhou Institute of Biological Products Co., Ltd

Jiangsu Jindik Biotechnology Co., Ltd

Jiangsu Kangrun Biotechnology Co., Ltd

Hualan Bio Vaccines Co., Ltd

Dalian Yalifeng Biopharmaceutical Co., Ltd

Zhejiang Tian Yuan Biopharmaceutical Co., Ltd

Emmi Chengxin Biopharmaceutical Co., Ltd

List of Tables

Table 1. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Inactivated Influenza Virus Vaccine Market Competitive Situation by Manufacturers in 2023

Table 4. Global Inactivated Influenza Virus Vaccine Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Inactivated Influenza Virus Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Inactivated Influenza Virus Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Inactivated Influenza Virus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Virus Vaccine as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Inactivated Influenza Virus Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Inactivated Influenza Virus Vaccine Sales by Region (2019-2024) & (K Units)

Table 18. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2019-2024)

Table 19. Global Inactivated Influenza Virus Vaccine Sales by Region (2025-2030) & (K Units)

Table 20. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2025-2030)

Table 21. Global Inactivated Influenza Virus Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2019-2024)

Table 23. Global Inactivated Influenza Virus Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2025-2030)

Table 25. North America Inactivated Influenza Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Inactivated Influenza Virus Vaccine Sales by Country (2019-2024) & (K Units)

Table 27. North America Inactivated Influenza Virus Vaccine Sales by Country (2025-2030) & (K Units)

Table 28. North America Inactivated Influenza Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Inactivated Influenza Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Inactivated Influenza Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Inactivated Influenza Virus Vaccine Sales by Country (2019-2024) & (K Units)

Table 32. Europe Inactivated Influenza Virus Vaccine Sales by Country (2025-2030) & (K Units)

Table 33. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Inactivated Influenza Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Inactivated Influenza Virus Vaccine Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Inactivated Influenza Virus Vaccine Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Inactivated Influenza Virus Vaccine Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Inactivated Influenza Virus Vaccine Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Type (2019-2024)

Table 51. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Type (2025-2030)

Table 52. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2019-2024)

Table 53. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2025-2030)

Table 54. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2019-2024)

Table 57. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2025-2030)

Table 58. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Type (2019-2024)

Table 59. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Type (2025-2030)

Table 60. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Application (2019-2024)

Table 61. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Application (2025-2030)

Table 62. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2019-2024)

Table 63. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2025-2030)

Table 64. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2019-2024)

Table 67. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2025-2030)

Table 68. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Application (2019-2024)

Table 69. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Application (2025-2030)

Table 70. CSL Corporation Information

Table 71. CSL Description and Business Overview

Table 72. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. CSL Inactivated Influenza Virus Vaccine Product

Table 74. CSL Recent Developments/Updates

Table 75. GSK Corporation Information

Table 76. GSK Description and Business Overview

Table 77. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. GSK Inactivated Influenza Virus Vaccine Product

Table 79. GSK Recent Developments/Updates

Table 80. Sanofi Pasteur Corporation Information

Table 81. Sanofi Pasteur Description and Business Overview

Table 82. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product

Table 84. Sanofi Pasteur Recent Developments/Updates

Table 85. Mylan Corporation Information

Table 86. Mylan Description and Business Overview

Table 87. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Mylan Inactivated Influenza Virus Vaccine Product

Table 89. Mylan Recent Developments/Updates

Table 90. AstraZeneca Corporation Information

Table 91. AstraZeneca Description and Business Overview

Table 92. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. AstraZeneca Inactivated Influenza Virus Vaccine Product

Table 94. AstraZeneca Recent Developments/Updates

Table 95. Pfizer Corporation Information

Table 96. Pfizer Description and Business Overview

Table 97. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Pfizer Inactivated Influenza Virus Vaccine Product

Table 99. Pfizer Recent Developments/Updates

Table 100. Johnson & Johnson Corporation Information

Table 101. Johnson & Johnson Description and Business Overview

Table 102. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Johnson & Johnson Inactivated Influenza Virus Vaccine Product

Table 104. Johnson & Johnson Recent Developments/Updates

Table 105. Jiangsu Jindik Biotechnology Co., Ltd Corporation Information

Table 106. Jiangsu Jindik Biotechnology Co., Ltd Description and Business Overview

Table 107. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 109. Jiangsu Jindik Biotechnology Co., Ltd Recent Developments/Updates

Table 110. Beijing Kexing Biological Products Co., Ltd Corporation Information

Table 111. Beijing Kexing Biological Products Co., Ltd Description and Business Overview

Table 112. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 114. Beijing Kexing Biological Products Co., Ltd Recent Developments/Updates

Table 115. Jiangsu Kangrun Biotechnology Co., Ltd Corporation Information

Table 116. Jiangsu Kangrun Biotechnology Co., Ltd Description and Business Overview

Table 117. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 119. Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments/Updates

Table 120. Hualan Bio Vaccines Co., Ltd Corporation Information

Table 121. Hualan Bio Vaccines Co., Ltd Description and Business Overview

Table 122. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 124. Hualan Bio Vaccines Co., Ltd Recent Developments/Updates

Table 125. Dalian Yalifeng Biopharmaceutical Co., Ltd Corporation Information

Table 126. Dalian Yalifeng Biopharmaceutical Co., Ltd Description and Business Overview

Table 127. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 129. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments/Updates

Table 130. Shanghai Institute of Biological Products Co., Ltd Corporation Information

Table 131. Shanghai Institute of Biological Products Co., Ltd Description and Business Overview

Table 132. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 134. Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates

Table 135. Changchun Institute of Biological Products Co., Ltd Corporation Information

Table 136. Changchun Institute of Biological Products Co., Ltd Description and Business Overview

Table 137. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 139. Changchun Institute of Biological Products Co., Ltd Recent Developments/Updates

Table 140. Lanzhou Institute of Biological Products Co., Ltd Corporation Information

Table 141. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview

Table 142. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 143. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 144. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates

Table 145. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Corporation Information

Table 146. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Description and Business Overview

Table 147. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 148. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 149. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments/Updates

Table 150. Emmi Chengxin Biopharmaceutical Co., Ltd Corporation Information

Table 151. Emmi Chengxin Biopharmaceutical Co., Ltd Description and Business Overview

Table 152. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 153. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product

Table 154. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments/Updates

Table 155. Key Raw Materials Lists

Table 156. Raw Materials Key Suppliers Lists

Table 157. Inactivated Influenza Virus Vaccine Distributors List

Table 158. Inactivated Influenza Virus Vaccine Customers List

Table 159. Inactivated Influenza Virus Vaccine Market Trends

Table 160. Inactivated Influenza Virus Vaccine Market Drivers

Table 161. Inactivated Influenza Virus Vaccine Market Challenges

Table 162. Inactivated Influenza Virus Vaccine Market Restraints

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Inactivated Influenza Virus Vaccine

Figure 2. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Inactivated Influenza Virus Vaccine Market Share by Type in 2023 & 2030

Figure 4. Whole Virus Vaccine Product Picture

Figure 5. Subunit Vaccine Product Picture

Figure 6. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Inactivated Influenza Virus Vaccine Market Share by Application in 2023 & 2030

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Global Inactivated Influenza Virus Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Inactivated Influenza Virus Vaccine Market Size (2019-2030) & (US$ Million)

Figure 12. Global Inactivated Influenza Virus Vaccine Sales (2019-2030) & (K Units)

Figure 13. Global Inactivated Influenza Virus Vaccine Average Price (US$/Unit) & (2019-2030)

Figure 14. Inactivated Influenza Virus Vaccine Report Years Considered

Figure 15. Inactivated Influenza Virus Vaccine Sales Share by Manufacturers in 2023

Figure 16. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers in 2023

Figure 17. The Global 5 and 10 Largest Inactivated Influenza Virus Vaccine Players: Market Share by Revenue in 2023

Figure 18. Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 19. Global Inactivated Influenza Virus Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 20. North America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2019-2030)

Figure 21. North America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2019-2030)

Figure 22. United States Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 23. Canada Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Country (2019-2030)

Figure 25. Europe Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2019-2030)

Figure 26. Germany Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. France Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. U.K. Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Italy Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Russia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Inactivated Influenza Virus Vaccine Sales Market Share by Region (2019-2030)

Figure 32. Asia Pacific Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2019-2030)

Figure 33. China Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Japan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. South Korea Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. India Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Australia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. China Taiwan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Latin America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2019-2030)

Figure 41. Latin America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2019-2030)

Figure 42. Mexico Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Brazil Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Argentina Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Inactivated Influenza Virus Vaccine Sales Market Share by Country (2019-2030)

Figure 46. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2019-2030)

Figure 47. Turkey Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. UAE Inactivated Influenza Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Global Sales Market Share of Inactivated Influenza Virus Vaccine by Type (2019-2030)

Figure 51. Global Revenue Market Share of Inactivated Influenza Virus Vaccine by Type (2019-2030)

Figure 52. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Type (2019-2030)

Figure 53. Global Sales Market Share of Inactivated Influenza Virus Vaccine by Application (2019-2030)

Figure 54. Global Revenue Market Share of Inactivated Influenza Virus Vaccine by Application (2019-2030)

Figure 55. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Application (2019-2030)

Figure 56. Inactivated Influenza Virus Vaccine Value Chain

Figure 57. Inactivated Influenza Virus Vaccine Production Process

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Distributors Profiles

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions